D2A21

Drug Profile

D2A21

Alternative Names: D2A21 gel - Demegen; Demegel; Peptidyl MIM; Provena

Latest Information Update: 25 Feb 2008

Price : $50

At a glance

  • Originator Demegen
  • Developer Demegen; DFB Pharmaceuticals
  • Class Antibacterials; Peptide antibiotics
  • Mechanism of Action Apoptosis stimulants; Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Burn infections; Cancer; Protozoan infections; Wound infections

Most Recent Events

  • 27 Jun 2003 Suspended - Preclinical for Protozoal infections in USA (Topical)
  • 27 Jun 2003 Suspended - Preclinical for Wound infections in USA (Topical)
  • 27 Jun 2003 Suspended - Preclinical for Burn infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top